LM-101, an anti-SIRPα antibody, in patients with relapsed/refractory lymphoma and advanced head and neck cancer: an open-label, multicenter, phase 1 trial

Key Points

• The study aims to evaluate the safety and initial efficacy of LM-101 in treating relapsed/refractory lymphoma and advanced head and neck cancer.
• Open-label, multicenter design
• Administration of LM-101 antibody
• Inclusion of patients with relapsed/refractory lymphoma and advanced head and neck cancer
• LM-101 was well tolerated among patients
• Preliminary efficacy signal indicates potential benefit of LM-101 combined with rituximab

Abstract